• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description.

作者信息

van Damme Claire, Sibaud Vincent, André Josette, Richert Bertrand, Berlingin Evelyne

机构信息

Dermatology Department, Ambroise Paré University Hospital Center, Mons, Belgium.

Oncodermatology Department, Institut Claudius Regaud and Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.

出版信息

JAAD Case Rep. 2021 Mar 2;10:110-112. doi: 10.1016/j.jdcr.2021.02.016. eCollection 2021 Apr.

DOI:10.1016/j.jdcr.2021.02.016
PMID:33816737
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8010201/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7803/8010201/3d0c54a9e118/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7803/8010201/81e697a23fb5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7803/8010201/3d0c54a9e118/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7803/8010201/81e697a23fb5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7803/8010201/3d0c54a9e118/gr2.jpg

相似文献

1
Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description.抗程序性细胞死亡蛋白1诱导的甲单位苔藓样改变：组织病理学描述。
JAAD Case Rep. 2021 Mar 2;10:110-112. doi: 10.1016/j.jdcr.2021.02.016. eCollection 2021 Apr.
2
Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.接受抗PD-L1和抗PD-1治疗患者苔藓样反应的免疫组织化学分析
J Cutan Pathol. 2016 Apr;43(4):339-46. doi: 10.1111/cup.12666. Epub 2016 Feb 10.
3
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.免疫检查点抑制剂的皮肤不良反应：皮肤毒性与免疫治疗
Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
4
Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.大疱性扁平苔藓与抗程序性细胞死亡-1治疗：病例报告及文献综述
Ann Dermatol Venereol. 2020 Mar;147(3):221-227. doi: 10.1016/j.annder.2019.07.008. Epub 2020 Jan 22.
5
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.抗PD-1或抗PD-L1免疫疗法诱导的血液学免疫相关不良事件：一项描述性观察研究。
Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.
6
Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.接受抗程序性死亡受体 1 免疫治疗的肺癌患者接种流感疫苗不会引起免疫相关不良事件。
Eur J Cancer. 2018 Nov;104:182-187. doi: 10.1016/j.ejca.2018.09.012. Epub 2018 Oct 24.
7
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.抗程序性死亡-1药物治疗后不良事件的管理
Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8.
8
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.与 PD-1 抑制剂治疗相关的口腔免疫相关不良事件：病例系列研究。
Oral Dis. 2020 Mar;26(2):325-333. doi: 10.1111/odi.13218. Epub 2020 Jan 9.
9
Drug-induced oral lichenoid reaction during nivolumab therapy.纳武利尤单抗治疗期间药物引起的口腔苔藓样反应。
Int J Oral Maxillofac Surg. 2019 Apr;48(4):488-491. doi: 10.1016/j.ijom.2018.07.025. Epub 2018 Aug 28.
10
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.免疫相关不良事件与非小细胞肺癌的程序性细胞死亡蛋白-1 和程序性死亡配体 1 抑制剂相关：PRISMA 系统评价和荟萃分析。
BMC Cancer. 2019 Jun 10;19(1):558. doi: 10.1186/s12885-019-5701-6.

引用本文的文献

1
Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies.Foxp3+ 调节性 T 细胞（Foxp3+Treg）的研究进展及其在消化道恶性肿瘤中的关键作用。
Front Immunol. 2024 Jun 11;15:1404974. doi: 10.3389/fimmu.2024.1404974. eCollection 2024.
2
Nivolumab Safety in Renal Cell Carcinoma: A Case Report.纳武单抗在肾细胞癌中的安全性：一例报告。
J Pharm Technol. 2024 Apr;40(2):112-117. doi: 10.1177/87551225231218164. Epub 2023 Dec 15.
3
Mucocutaneous adverse events to immune checkpoint inhibitors.免疫检查点抑制剂的皮肤黏膜不良事件。

本文引用的文献

1
The interface reaction pattern in the skin: an integrated review of clinical and pathological features.皮肤的界面反应模式：临床与病理特征的综合综述。
Hum Pathol. 2019 Sep;91:86-113. doi: 10.1016/j.humpath.2019.06.004. Epub 2019 Jul 3.
2
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.免疫相关性皮肤不良反应的治疗结果。
J Clin Oncol. 2019 Oct 20;37(30):2746-2758. doi: 10.1200/JCO.18.02141. Epub 2019 Jun 19.
3
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Front Allergy. 2023 Mar 2;4:1147513. doi: 10.3389/falgy.2023.1147513. eCollection 2023.
4
Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.皮肤免疫相关不良事件：毒性谱及管理建议。
Int J Womens Dermatol. 2021 Oct 23;7(5Part A):625-635. doi: 10.1016/j.ijwd.2021.10.005. eCollection 2021 Dec.
免疫检查点抑制剂治疗相关炎症性皮疹：毒性分层的单机构回顾性分析及其对治疗的影响。
J Am Acad Dermatol. 2019 Apr;80(4):990-997. doi: 10.1016/j.jaad.2018.10.062. Epub 2018 Nov 3.
4
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.靶向治疗和免疫治疗的皮肤、口腔黏膜、头发和指甲毒性副作用。
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39. doi: 10.1007/s40257-018-0384-3.
5
A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy.一例接受纳武单抗治疗后新发掌跖银屑病伴银屑病关节炎和自身免疫性甲状腺功能减退症的病例。
Dermatol Online J. 2017 Aug 15;23(8):13030/qt12n4m6pm.
6
Nivolumab-induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin.
Clin Exp Dermatol. 2018 Jul;43(5):609-610. doi: 10.1111/ced.13410. Epub 2018 Feb 16.
7
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.免疫检查点抑制剂的皮肤不良反应：皮肤毒性与免疫治疗
Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
8
Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review.伴用皮质类固醇和免疫检查点抑制剂治疗血液系统或实体瘤患者：系统评价。
Crit Rev Oncol Hematol. 2017 Dec;120:86-92. doi: 10.1016/j.critrevonc.2017.10.009. Epub 2017 Oct 27.
9
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.抗程序性细胞死亡蛋白1和抗程序性细胞死亡配体1免疫治疗所致苔藓样皮肤黏膜疹的临床和组织学特征
JAMA Dermatol. 2016 Oct 1;152(10):1128-1136. doi: 10.1001/jamadermatol.2016.2226.
10
Pembrolizumab: a new Drug That Can Induce Exacerbations of Psoriasis.帕博利珠单抗：一种可诱发银屑病病情加重的新药。
Actas Dermosifiliogr. 2016 Apr;107(3):264-6. doi: 10.1016/j.ad.2015.07.012. Epub 2015 Nov 3.